Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...
“With the approval of JOURNAVX, a non-opioid ... we have the opportunity to change the paradigm of acute painmanagement and establish a new standard of care.” The approval is considered ...